Printer Friendly

CELOX CORPORATION FILES TRADEMARK SUIT AGAINST FORMER ENDOTRONICS

 MINNEAPOLIS, June 29 /PRNewswire/ -- Celox Corporation (NASDAQ: CELX) today announced that it has filed suit in federal district court against Cellex Biosciences, Inc., formerly known as Endotronics.
 Celox alleges that the adoption of the new name, Cellex, along with its adoption of the stock symbol, CLXX by the former Endotronics, violates federal trademark law protecting Celox's use of its name since 1985 and also violates Minnesota's Deceptive Trade Practice Act.
 The suit seeks to prohibit the former Endotronics from using the Cellex name it began using May 1993, and seeks damages in excess of $50,000.
 "This infringement of our name has already caused significant and harmful confusion among our customers, shareholders and in the scientific and financial communities," said Milo R. Polovina, Celox's president and CEO.
 Recently, Celox filed registration with the Food & Drug Administration (FDA) to become a medical device company, which will allow it to sell its product to diagnose human disease.
 Celox is a biotechnology company that specializes in improving the physiological condition of human cells and cells from other species. Celox pioneered the development of non-serum cell biology products used in researching and developing diagnostics and therapeutics for major health problems such as AIDS and cancer.
 -0- 6/29/93
 /CONTACT: Milo R. Polovina, president & CEO of Celox Corporation, 612-933-2616; or Gail D. Shore of Shore to Shore Communications, 612-925-6102, for Celox Corporation/
 (CELX)


CO: Celox Corporation ST: Minnesota IN: MTC SU:

DB -- MN006 -- 6656 06/29/93 11:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:246
Previous Article:CROCKER REALTY INVESTORS CLOSES ON PURCHASE OF ARVIDA FINANCIAL PLAZA; ANNOUNCES TWO LEASES, RENOVATION PLANS
Next Article:GLIATECH'S ADCON-L EFFICACIOUS IN PRECLINICAL TESTING; STUDY PUBLISHED IN JOURNAL OF NEUROSURGERY
Topics:


Related Articles
CELOX ANNOUNCES MARKETING AGREEMENT
CELOX CORPORATION ANNOUNCES APPOINTMENT
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE
CELLEX BIOSCIENCES, INC. DEFENDS CLAIM OF TRADEMARK INFRINGEMENT
CELOX CORPORATION BOARD AUTHORIZES STOCK REPURCHASE
CELOX CORPORATION HIRES SALES MANAGER
CELOX CORPORATION NAMES SALES AND MARKETING VICE PRESIDENT
CELOX CORPORATION INCREASED SALES IN FIRST QUARTER
CELOX CORPORATION AND AMERICAN TYPE CULTURE COLLECTION TO OFFER SERUM FREE CELL LINES
CELOX CORPORATION ANNOUNCES 1994 FINANCIAL RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters